Talnetant
Talnetant
Talnetant (pronounced: /tælˈnɛtænt/) is a neurokinin 3 receptor antagonist that was under development for the treatment of schizophrenia and other central nervous system disorders. It was developed by GlaxoSmithKline but its development was discontinued in 2009.
Etymology
The term "Talnetant" is a coined name, with no specific etymology. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new drugs.
Pharmacology
Talnetant acts by blocking the neurokinin 3 receptor, a protein that is involved in the transmission of pain signals in the body. By blocking this receptor, Talnetant can potentially reduce the symptoms of conditions such as schizophrenia and other central nervous system disorders.
Clinical Trials
Talnetant underwent Phase II clinical trials for the treatment of schizophrenia. However, the development of the drug was discontinued in 2009 due to lack of efficacy in the trials.
Related Terms
External links
- Medical encyclopedia article on Talnetant
- Wikipedia's article - Talnetant
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski